Veracyte has been granted a patent for a method of determining if a subject has usual interstitial pneumonia (UIP). The method involves performing imaging analysis, obtaining a biological sample, assaying nucleic acid molecules, and using a classifier to differentiate between UIP and other non-UIP subtypes. The patent aims to provide improved sequencing and analysis of nucleic acids for accurate diagnosis. GlobalData’s report on Veracyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Veracyte, ML-based biomarker screening was a key innovation area identified from patents. Veracyte's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method for determining usual interstitial pneumonia (uip) in subjects
A recently granted patent (Publication Number: US11639527B2) describes a method for determining whether a subject has usual interstitial pneumonia (UIP), a type of interstitial lung disease. The method involves several steps. First, an imaging analysis is performed on the subject, which may not provide a conclusive result. Subsequently, a biological sample is obtained from the subject. Nucleic acid molecules derived from the sample are then assayed to identify the expression level of a group of genes associated with UIP. A classifier is used to process this expression level and generate a classification of the biological sample as positive for UIP. Importantly, the classifier is designed to differentiate between UIP and several other non-UIP subtypes, including hypersensitivity pneumonitis, non-specific interstitial pneumonia, sarcoidosis, respiratory bronchiolitis, bronchiolitis, diffuse alveolar damage, and organizing pneumonia.
The biological sample used in the method can be a transbronchial biopsy sample or a bronchoalveolar lavage sample. The assay step may involve sequencing the nucleic acid molecules. Additionally, the assay may also identify the expression level of at least one control nucleic acid molecule in the sample. The classifier used in the method employs a machine learning algorithm that has been trained to identify UIP from the non-UIP subtypes. Importantly, the training set used for the algorithm is independent of the biological sample being analyzed.
The biological sample can be either fresh-frozen or fixed, and the nucleic acid molecules assayed are ribonucleic acids (RNA) molecules. The method is intended for subjects who are suspected of having an interstitial lung disease based on clinical signs or symptoms. These signs may include shortness of breath or dry cough, while clinical signs may involve the results of a pulmonary function test or a lung tissue analysis. Examples of pulmonary function tests include spirometry, oximetry, or an exercise stress test, while lung tissue analysis may involve histological or cytological analysis of a lung tissue sample.
The imaging analysis mentioned in the method can be performed using chest X-ray or computerized tomography (CT). If CT is used, it is specified that high-resolution CT is preferred. Finally, based on the classification generated by the method, a therapeutic intervention can be provided to the subject.
In summary, this granted patent describes a method for determining whether a subject has UIP, a specific type of interstitial lung disease. The method involves imaging analysis, nucleic acid assay, and the use of a classifier to differentiate UIP from other non-UIP subtypes. The method can be used with different types of biological samples and involves the analysis of gene expression levels. The classification generated by the method can guide therapeutic interventions for the subject.